1 Pearson-Stuttard J, "Worldwide burden of cancer attributable to diabetes and high body-mass index : a comparative risk assessment" 6 : e6-e15, 2018
2 Burstein HJ, "Use of the peroxisome proliferator-activated receptor(PPAR)gamma ligand troglitazone as treatment for refractory breast cancer : a phase II study" 79 : 391-397, 2003
3 Noto H, "Unfolding link between diabetes and cancer" 9 : 473-474, 2018
4 Yu F, "Type 2 diabetes mellitus and risk of colorectal adenoma : a meta-analysis of observational studies" 16 : 642-, 2016
5 Shlomai G, "Type 2 diabetes mellitus and cancer : the role of pharmacotherapy" 34 : 4261-4269, 2016
6 Tsilidis KK, "Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies" 350 : g7607-, 2015
7 Lim D, "Trends in major cancer mortality in Korea, 1983-2012, with a joinpoint analysis" 39 : 939-946, 2015
8 서민아, "Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2013" 대한암학회 48 (48): 1-10, 2016
9 Monami M, "Thiazolidinediones and cancer : results of a meta-analysis of randomized clinical trials" 51 : 91-101, 2014
10 McBean AM, "The underuse of screening services among elderly women with diabetes" 30 : 1466-1472, 2007
11 Greenwood M, "The relation between the cancer and diabetes death-rates" 14 : 83-118, 1914
12 Ko C, "The need for a multidisciplinary approach to cancer care" 105 : 53-57, 2002
13 김경진, "Ten-Year Mortality Trends for Adults with and without Diabetes Mellitus in South Korea, 2003 to 2013" 대한당뇨병학회 42 (42): 394-401, 2018
14 Noto H, "Significantly increased risk of cancer in diabetes mellitus patients : a meta-analysis of epidemiological evidence in Asians and non-Asians" 3 : 24-33, 2012
15 Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomized controlled trial" 366 : 1279-1289, 2005
16 Monami M, "Safety issues with glucagon-like peptide-1 receptor agonists(pancreatitis, pancreatic cancer and cholelithiasis) : data from randomized controlled trials" 19 : 1233-1241, 2017
17 Tang H, "SGLT2 inhibitors and risk of cancer in type 2 diabetes : a systematic review and meta-analysis of randomized controlled trials" 60 : 1862-1872, 2017
18 강유미, "Role of NO/VASP Signaling Pathway against Obesity- Related Inflammation and Insulin Resistance" 대한당뇨병학회 41 (41): 89-95, 2017
19 Overbeek JA, "Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis" 34 : e3004-, 2018
20 진상만, "Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study" 대한의학회 29 (29): 238-242, 2014
21 Anothaisintawee T, "Risk factors of breast cancer : a systematic review and meta-analysis" 25 : 368-387, 2013
22 Heckman-Stoddard BM, "Repurposing metformin for the prevention of cancer and cancer recurrence" 60 : 1639-1647, 2017
23 Lipscombe LL, "Reduced screening mammography among women with diabetes" 165 : 2090-2095, 2005
24 Huang Y, "Prediabetes and the risk of cancer : a meta-analysis" 57 : 2261-2269, 2014
25 Lewis JD, "Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes" 314 : 265-277, 2015
26 Mehtälä J, "Pioglitazone use and risk of bladder cancer : a systematic literature review and meta-analysis of observational studies" 10 : 24-36, 2018
27 Ryder RE, "Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit" 32 : 305-313, 2015
28 Yee LD, "Pilot study of rosiglitazone therapy in women with breast cancer : effects of short-term therapy on tumor tissue and serum markers" 13 : 246-252, 2007
29 Wu L, "Pharmacologic therapy of diabetes and overall cancer risk and mortality : a meta-analysis of 265 studies" 5 : 10147-, 2015
30 Calle EE, "Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms" 4 : 579-591, 2004
31 Pollak M, "Overcoming drug development bottlenecks with repurposing : repurposing biguanides to target energy metabolism for cancer treatment" 20 : 591-593, 2014
32 Ricart W, "No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance" 9 : 631-636, 2001
33 Lee JH, "New-onset diabetes patients need pancreatic cancer screening?" 46 : e58-e61, 2012
34 Kang YM, "Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013" 15 : 131-, 2016
35 Thakkar B, "Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies" 62 : 922-934, 2013
36 Gandini S, "Metformin and cancer risk and mortality : a systematic review and meta-analysis taking into account biases and confounders" 7 : 867-885, 2014
37 Barone BB, "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and meta-analysis" 300 : 2754-2764, 2008
38 van de Poll-Franse LV, "Less aggressive treatment and worse overall survival in cancer patients with diabetes : a large population based analysis" 120 : 1986-1992, 2007
39 서성환, "Korean Type 2 Diabetes Patients have Multiple Adenomatous Polyps Compared to Non-diabetic Controls" 대한의학회 26 (26): 1196-1200, 2011
40 Sciacca L, "Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling" 53 : 1743-1753, 2010
41 Renehan AG, "Insulin analogues and cancer risk : the emergence of second-generation studies" 55 : 7-9, 2012
42 Zhang Z, "Incretin-based agents in type 2 diabetic patients at cardiovascular risk : compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes" 16 : 31-, 2017
43 Sommerfeld MR, "In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites" 5 : e9540-, 2010
44 Cho NH, "IDF Diabetes Atlas : global estimates of diabetes prevalence for 2017 and projections for 2045" 138 : 271-281, 2018
45 류태영, "Hyperglycemia as a Risk Factor for Cancer Progression" 대한당뇨병학회 38 (38): 330-336, 2014
46 Barclay AW, "Glycemic index, glycemic load, and chronic disease risk : a meta-analysis of observational studies" 87 : 627-637, 2008
47 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017" 392 : 1789-1858, 2018
48 GBD 2017 Causes of Death Collaborators, "Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017 : a systematic analysis for the Global Burden of Disease Study 2017" 392 : 1736-1788, 2018
49 Arnold M, "Global burden of cancer attributable to high body-mass index in 2012 : a population-based study" 16 : 36-46, 2015
50 Tancredi M, "Excess mortality among persons with type 2 diabetes" 373 : 1720-1732, 2015
51 Sacerdote C, "Epidemiological dimensions of the association between type 2 diabetes and cancer : a review of observational studies" 143 : 369-377, 2018
52 Pasello G, "Effects of sulfonylureas on tumor growth : a review of the literature" 18 : 1118-1125, 2013
53 Liu X, "Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK" 111 : E435-E444, 2014
54 Pinto LC, "Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis : a meta-analysis with trial sequential analysis" 8 : 782-, 2018
55 Chen L, "Diabetes treatments and risks of adverse breast cancer outcomes among early-stage breast cancer patients : a SEER-medicare analysis" 77 : 6033-6041, 2017
56 Coughlin SS, "Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults" 159 : 1160-1167, 2004
57 Gordon-Dseagu VL, "Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease : evidence from the Health Survey for England and Scottish Health Survey cohorts" 28 : 791-797, 2014
58 Hua F, "Diabetes and cancer, common threads and missing links" 374 : 54-61, 2016
59 Renehan AG, "Diabetes and cancer(2) : evaluating the impact of diabetes on mortality in patients with cancer" 55 : 1619-1632, 2012
60 Cignarelli A, "Diabetes and cancer : pathophysiological fundamentals of a ‘dangerous affair’" 143 : 378-388, 2018
61 Giovannucci E, "Diabetes and cancer : a consensus report" 33 : 1674-1685, 2010
62 Badrick E, "Diabetes and cancer : 5 years into the recent controversy" 50 : 2119-2125, 2014
63 서성환, "Diabetes and Cancer: Is Diabetes Causally Related to Cancer?" 대한당뇨병학회 35 (35): 193-198, 2011
64 Sen Li, "Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study" 대한당뇨병학회 43 (43): 319-341, 2019
65 ORIGIN Trial Investigators, "Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids(ORIGINALE)" 39 : 709-716, 2016
66 쿰반월터척, "Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007-2009" 한국역학회 39 : 1-8, 2017
67 Harding JL, "Cancer risk among people with type 1 and type 2 diabetes : disentangling true associations, detection bias, and reverse causation" 38 : 264-270, 2015
68 Carstensen B, "Cancer incidence in persons with type 1 diabetes : a five-country study of 9, 000 cancers in type 1 diabetic individuals" 59 : 980-988, 2016
69 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015" 대한암학회 50 (50): 303-316, 2018
70 Starup-Linde J, "CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants. A systematic review and a meta-analysis" 8 : 296-332, 2013
71 Byers T, "Body fatness as a cause of cancer : epidemiologic clues to biologic mechanisms" 22 : R125-R134, 2015
72 ORIGIN Trial Investigators, "Basal insulin and cardiovascular and other outcomes in dysglycemia" 367 : 319-328, 2012
73 Chen Y, "Association between type 2 diabetes and risk of cancer mortality : a pooled analysis of over 771, 000 individuals in the Asia Cohort Consortium" 60 : 1022-1032, 2017
74 Xu J, "Association between markers of glucose metabolism and risk of colorectal cancer" 6 : e011430-, 2016
75 Ptaszynska A, "Assessing bladder cancer risk in type 2 diabetes clinical trials : the dapagliflozin drug development program as a ‘case study’" 6 : 357-375, 2015
76 Tseng CH, "An updated review on cancer risk associated with incretin mimetics and enhancers" 33 : 67-124, 2015
77 Kyrgiou M, "Adiposity and cancer at major anatomical sites : umbrella review of the literature" 356 : j477-, 2017
78 Terzolo M, "Acromegaly is associated with increased cancer risk : a survey in Italy" 24 : 495-504, 2017
79 Romera I, "A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes" 10 : 5-19, 2019
80 Kulke MH, "A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer" 8 : 395-399, 2002
81 Lim SS, "A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010" 380 : 2224-2260, 2012
82 American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. 2019" 42 (42): S90-S102, 2019
83 American Diabetes Association, "4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes. 2019" 42 (42): S34-S45, 2019